Page 1

in + Close RNS Number : 2794R Hikma Pharmaceuticals Plc 04 November 2021 London , 4 November 2021 - Hikma Pharmaceuticals PLC ( Hikma , Group ) , the multinational pharmaceutical group , today provides an update on current trading . Siggi Olafsson , Hikma's CEO , said : " Our business continues to perform strongly , enabling us to reiterate our full year guidance to achieve another year of growth . We have made excellent progress year to date , including launching new specialty products , establishing new partnerships and using our robust balance sheet to expand our portfolio and pipeline . While the global pandemic continues to bring some volatility , we are leveraging our resilient commercial and operational capabilities to drive growth and to reliably deliver medicines to our customers and patients . " Injectables Our global Injectables business is performing well . In the US , we remain on track to deliver growth for the full year , benefitting from the breadth of our portfolio , which is now over 120 products and includes 14 products launched in the year to date . While elective surgeries remain below pre - pandemic levels , our flexible , high quality manufacturing capabilities and resilient supply chain continue to underpin our ability to provide a consistent supply of medicines to our customers . We are also making good strategic progress in the US , where we recently announced our first US biosimilar partnership - an exclusive licensing agreement with Bio - Thera to commercialise their proposed biosimilar referencing StelaraⓇ ( ustekinumab ) . In addition , we have agreed to acquire Custopharm , a US - based generic sterile injectables company with a differentiated product portfolio and R & D pipeline . The transaction is subject to US Federal Trade Commission approval . In Europe , we are delivering strong growth from our own products , including some COVID - 19 related medicines . We also continue to utilise our flexible manufacturing capacity for contract manufacturing opportunities . In MENA , we are seeing good demand across most of our markets and are increasing our investment in the expansion of local manufacturing capacity . We continue to expect global Injectables revenue to grow in the mid - single digits and core operating margin to be in the range of 37 % to 38 % . Generics Our Generics business is continuing the strong performance seen in the first half . This reflects good performance from our in - market products as well as a strong contribution from recent launches , which are more than offsetting expected price erosion on our base business . We are making good progress expanding our portfolio and pipeline for this business , especially with respect to our specialty portfolio , which will be an increasingly important driver of future growth . In August we launched KLOXXADOTM ( naloxone hydrochloride ) nasal spray 8mg , which has received good feedback in the community health and addiction therapy market . We are also building our portfolio of specialty allergy treatments , signing an exclusive license agreement with FAES Farma S.A. in September to commercialise Bilastine tablets , a non - sedating second generation antihistamine . We continue to expect our full year Generics revenue to be in the range of $ 810 million to $ 830 million and we now expect core operating margin to be closer to the top end of our guidance range of 22 % to 24 % , reflecting a more favorable product mix . Branded The Branded business is performing well , in - line with our expectations . Algeria is a top performer , with strong demand across the portfolio and a good performance from recently launched products . We are also seeing good demand in most of our other markets . Across the region , we have seen a strong rebound in demand for anti - infectives and are making progress in the launch of new products , including the launch of five locally manufactured oncology products in Algeria . Building our global network of partners is a key area of focus for this business . We recently announced an exclusive license agreement with Almirall S.A. to commercialise Finjuve TM , a finasteride spray for the treatment of androgenic alopecia , in certain MENA markets . We continue to expect Branded revenue growth in constant currency to be in the mid - single digits for the full year in 2021 . We will announce our preliminary results for the year ended 31 December 2021 on 24 February 2022 . Enquiries : Hikma ( Investors ) Susan Ringdal ENDS +44 ( 0 ) 20 7399 2760 / +44 7776 477050 EVP , Strategic Planning and Global Affairs